Epithelial-mesenchymal transition and drug resistance: Role, molecular mechanisms, and therapeutic strategies

Oncology Research and Treatment

Volumn 37, Issue 10, 2014, Pages 584-589

  Sui, Hua ^a   Zhu, Lei ^b   Deng, Wanli ^c   Li, Qi ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b Department of Internal Medicine IV Changji Traditional Chinese Medical Hospital of Xinjiang   (China)

^c XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

Drug resistance; Epithelial mesenchymal transition; Microenvironment; microRNAs; Signal transduction pathway

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CURCUMIN; ERLOTINIB; GEFITINIB; HYPOXIA INDUCIBLE FACTOR 1; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; TUMOR PROTEIN;

CANCER CHEMOTHERAPY; CANCER RESISTANCE; DRUG RESISTANCE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANIMAL; BIOLOGICAL MODEL; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; NEOPLASMS; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NEOPLASMS;

EID: 84908602903     PISSN: 22965270     EISSN: 22965262     Source Type: Journal    
DOI: 10.1159/000367802     Document Type: Review

References (59)

1. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15.
2. Gros J, Tabin CJ: Vertebrate limb bud formation is initiated by localized epithelial-to-mesenchymal transition. Science 2014;343:1253-6.
3. Iyer AK, Singh A, Ganta S, Amiji MM: Role of integrated cancer nanomedicine in overcoming drug resistance. Adv Drug Deliv Rev 2013;65:1784-802.
4. Greenburg G, Hay ED: Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells. J Cell Biol 1982;95:333-9.
5. Thompson EW, Torri J, Sabol M, Sommers CL, Byers S, Valverius EM, Martin GR, Lippman ME, Stampfer MR, Dickson RB: Oncogene-induced basement membrane invasiveness in human mammary epithelial cells. Clin Exp Metastasis 1994;12: 181-94.
6. Savagner P, Boyer B, Valles AM, Jouanneau J, Thiery JP: Modulations of the epithelial phenotype during embryogenesis and cancer progression. Cancer Treat Res 1994;71:229-49.
7. Lai KP, Law AY, Lau MC, Takei Y, Tse WK, Wong CK: Osmotic stress transcription factor 1b (Ostf1b) promotes migration properties with the modulation of epithelial mesenchymal transition (EMT) phenotype in human embryonic kidney cell. Int J Biochem Cell Biol 2013;45:1921-6.
8. Thiery JP, Acloque H, Huang RY, Nieto MA: Epithelial- mesenchymal transitions in development and disease. Cell 2009;139:871-90.
9. Kang Y, Massagué J: Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004;118:277-9.
10. Xin H, Kong Y, Jiang X, Wang K, Qin X, Miao ZH, Zhu Y, Tan W: Multi-drug-resistant cells enriched from chronic myeloid leukemia cells by doxorubicin possess tumor-initiating-cell properties. J Pharmacol Sci 2013;122:299-304.
11. Olmeda D, Jorda M, Peinado H, Fabra A, Cano A: Snail silencing effectively suppresses tumour growth and invasiveness. Oncogene 2007;26:1862-74.
12. Peinado H, Olmeda D, Cano A: Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 2007;7:415-28.
13. Singh A, Settleman J: EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010;29:4741-51.
14. Mallini P, Lennard T, Kirby J, Meeson A: Epithelial-to-mesenchymal transition. What is the impact on breast cancer stem cells and drug resistance. Cancer Treat Rev 2013;pii:S0305-7372(13)00197-7.
15. Sui H, Fan ZZ Li Q: Signal transduction pathways and transcriptional mechanisms of MDR1/Pgpmediated multidrug resistance in human cancer cells. J Int Med Res 2012;40:426-35.
16. Sui H, Zhou SF, Wang Y, Liu X, Zhou L, Yin P, Fan Z, Li Q: COX-2 contributes to P-glycoproteinmediated multidrug resistance via phosphorylation of c-Jun at Ser63/73 in colorectal cancer. Carcinogenesis 2011;32:667-75.
17. Baguley BC: Multiple drug resistance mechanisms in cancer. Mol Biotechnol 2010;46:308-16.
18. Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, Iwata KK, Gibson N, Haley JD: Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 2005;65:9455-62.
19. Mallini P, Lennard T, Kirby J, Meeson A: Epithelial- to-mesenchymal transition: what is the impact on breast cancer stem cells and drug resistance. Cancer Treat Rev 2014;40:341-8.
20. Findlay VJ, Wang C, Watson DK, Camp ER: Epithelial-to-mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer. Cancer Gene Ther 2014;21:181-7.
21. Gupta N1, Xu Z, El-Sehemy A, Steed H, Fu Y: Notch3 induces epithelial-mesenchymal transition and attenuates carboplatin-induced apoptosis in ovarian cancer cells. Gynecol Oncol 2013;130:200-6.
22. Zhao J, Dong D, Sun L, Zhang G, Sun L: Prognostic significance of the epithelial-to-mesenchymal transition markers e-cadherin, vimentin and twist in bladder cancer. Int Braz J Urol 2014;40:179-189.
23. Li Y, Ma J, Qian X, Wu Q, Xia J, Miele L, Sarkar FH, Wang Z: Regulation of EMT by Notch signaling pathway in tumor progression. Curr Cancer Drug Targets 2013;13:957-62.
24. Mallini P, Lennard T, Kirby J, Meeson A: Epithelial-to-mesenchymal transition: what is the impact on breast cancer stem cells and drug resistance. Cancer Treat Rev 2014;40:341-8.
25. Cufí S, Martin AV, Ferraros CO, Martin-Castillo B, Joven J, Menendez JA: Metformin against TGFβ- induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle 2010;9:4461-8.
26. Li L, Jiang AC, Dong P, Wang H, Xu W, Xu C: MDR1/P-gp and VEGF synergistically enhance the invasion of Hep-2 cells with multidrug resistance induced by taxol. Ann Surg Oncol 2009;16: 1421-28.
27. Jang JY, Kim MK, Jeon YK, Joung YK, Park KD, Kim CW: Adenovirus adenine nucleotide translocator-2 shRNA effectively induces apoptosis and enhances chemosensitivity by the down-regulation of ABCG2 in breast cancer stem-like cells. Exp Mol Med 2012;44:251-9.
28. Saxena M, Stephens MA, Pathak H, Rangarajan A: Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis 2011;2:e179.
29. Liotta LA, Kohn EC: The microenvironment of the tumour-host interface. Nature 2001;411:375-9.
30. Spano D, Zollo M: Tumor microenvironment: a main actor in the metastasis process. Clin Exp Metastasis 2012;29:381-95.
31. Guan J, Zhang H, Wen Z, Gu Y, Cheng Y, Sun Y, Zhang T, Jia C, Lu Z, Chen J: Retinoic acid inhibits pancreatic cancer cell migration and EMT through the downregulation of IL-6 in cancer associated fibroblast cells. Cancer Lett 2014;345:132-9.
32. Acharya A1, Baek ST, Huang G, Eskiocak B, Goetsch S, Sung CY, Banfi S, Sauer MF, Olsen GS, Duffield JS, Olson EN, Tallquist MD: The bHLH transcription factor Tcf21 is required for lineagespecific EMT of cardiac fibroblast progenitors. Development 2012;139:2139-49.
33. Lisanti MP, Martinez-Outschoorn UE, Chiavarina B, Pavlides S, Whitaker-Menezes D, Tsirigos A, Witkiewicz A, Lin Z, Balliet R, Howell A, Sotgia F: Understanding the 'lethal' drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment. Cancer Biol Ther 2010;10:537-42.
34. Tredan O, Galmarini CM, Patel K, Tannock IF: Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007;99:1441-54.
35. Jabr-Milane LS, van Vlerken LE, Yadav S, Amiji MM: Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev 2008;34: 592-602.
36. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP: Hypoxia-inducible factor- 1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002;62:3387-94.
37. Liu L, Sun L, Zhang H, Li Z, Ning X, Shi Y, Guo C, Han S, Wu K, Fan D: Hypoxia-mediated up-regulation of MGr1-Ag/37LRP in gastric cancers occurs via hypoxia-inducible-factor 1-dependent mechanism and contributes to drug resistance. Int J Cancer 2009;124:1707-15.
38. Chai DM, Bao ZQ, Hu JG, Ma L, Feng ZZ, Tao YS: Vasculogenic mimicry and aberrant expression of HIF-1α/E-cad are associated with worse prognosis of esophageal squamous cell carcinoma. J Huazhong Univ Sci Technolog Med Sci 2013;33:385-91.
39. Jiao M, Nan KJ: Activation of PI3 kinase/Akt/ HIF-1α pathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma. Int J Oncol 2012;40:461-8.
40. Vincan E, Barker N: The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression. Clin Exp Metastasis 2008;25:657-63.
41. Yin X, Wolford CC, Chang YS, McConoughey SJ, Ramsey SA, Aderem A, Hai T: ATF3, an adaptiveresponse gene, enhances TGF(beta) signaling and cancer-initiating cell features in breast cancer cells. J Cell Sci 2010;123:3558-65.
42. Chen X, Lingala S, Khoobyari S, Nolta J, Zern MA, Wu J: Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations. J Hepatol 2011;55:838-45.
43. Han Z, Hong L, Han Y, Wu K, Han S, Shen H, Li C, Yao L, Qiao T, Fan D: Phospho Akt mediates multidrug resistance of gastric cancer cells through regulation of P-gp, Bcl-2 and Bax. J Exp Clin Cancer Res 2007;26:261-8.
44. Meyer zu Schwabedissen HE, Grube M, Dreisbach A, Jedlitschky G, Meissner K, Linnemann K, Fusch C, Ritter CA, Völker U, Kroemer HK: Epidermal growth factor-mediated activation of the map kinase cascade results in altered expression and function of ABCG2 (BCRP). Drug Metab Dispos 2006;34:524-33.
45. Chen SF, Nieh S, Jao SW, Liu CL, Wu CH, Chang YC, Yang CY, Lin YS: Quercetin suppresses drugresistant spheres via the p38 MAPK-Hsp27 apoptotic pathway in oral cancer cells. PLoS One 2012; 7:e49275.
46. Lander R, Nordin K, LaBonne C: The F-box protein Ppa is a common regulator of core EMT factors Twist, Snail, Slug, and Sip1. J Cell Biol 2011; 194:17-25.
47. Qu C, Zhang W, Zheng G, Zhang Z, Yin J, He Z: Metformin reverses multidrug resistance and epithelial- mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells. Mol Cell Biochem 2014; 386:63-71.
48. Kasinski AL, Slack FJ: Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011;11:849-64.
49. Esquela-Kerscher A, Slack FJ: Oncomirs - micro- RNAs with a role in cancer. Nat Rev Cancer 2006; 6:259-69.
50. Liu S, Kumar SM, Lu H, Liu A, Yang R, Pushparajan A, Guo W, Xu X: MicroRNA-9 up-regulates E-cadherin through inhibition of NF- B1-Snail1 pathway in melanoma. J Pathol 2012;226:61-72.
51. Nalls D, Tan SN, Rodova M, Srivastava RK, Shankar S: Targeting epigenetic regulation of miR- 34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS ONE 2011;6:1-12.
52. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1and SIP1. Nat Cell Biol 2008;10: 593-601.
53. Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF, Goodall GJ: A double-negative feedback loop between ZEB1-SIPI and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res 2008;68:7846-54.
54. Park SM, Gaur AB, Lengyel E, Peter ME: The miR- 200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008;22:894-907.
55. Pan YZ, Morris ME, Yu AM: MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol 2009;75:1374-9.
56. Chen Z, Ma T, Huang C, Zhang L, Lv X, Xu T, Hu T, Li J: MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/catenin pathway in hepatocellular carcinoma cells. Cell Signal 2013;25: 2693-701.
57. Chen CC, Sureshbabul M, Chen HW, Lin YS, Lee JY, Hong QS, Yang YC, Yu SL: Curcumin suppresses metastasis via Sp-1, FAK inhibition, and E-cadherin upregulation in colorectal cancer. Evid Based Complement Alternat Med 2013;2013:541695.
58. Liu L, Salnikov AV, Bauer N, Aleksandrowicz E, Labsch S, Nwaeburu C, Mattern J, Gladkich J, Schemmer P, Werner J, Herr I: Triptolide reverses hypoxia-induced epithelial-mesenchymal transition and stem-like features in pancreatic cancer by NF- B downregulation. Int J Cancer 2014;134:2489-503.
59. La Monica S1, Caffarra C, Saccani F, Galvani E, Galetti M, Fumarola C, Bonelli M, Cavazzoni A, Cretella D, Sirangelo R, Gatti R, Tiseo M, Ardizzoni A, Giovannetti E, Petronini PG, Alfieri RR: Gefitinib inhibits invasive phenotype and epithelial- mesenchymal transition in drug-resistant NSCLC cells with MET amplification. PLoS One 2013;8:e78656.